The team of investigators led by Daniel Jackson, MD, professor, Division of Allergy, Immunology, and Rheumatology, found a monoclonal antibody drug called mepolizumab decreased asthma attacks by 27% in children and adolescents who have a form of severe asthma, are prone to asthma attacks, and live in low-income urban neighborhoods, according to a clinical trial sponsored and co-funded by the National Institutes of Health. The majority of the trial’s participants were Black and/or Hispanic — populations that have been under-represented in clinical trials and are at greatest risk for morbidity and mortality from asthma.
The findings were published in the journal The Lancet.
Read the full story in the University of Wisconsin School of Medicine and Public Health press release.